Should I buy Manhattan Associates (MANH) stock or is it too late?
⭐ The most reliable of them, either direction: Stifel — 70% of its targets hit on this sector (205 calls tested). It aims for $225 (+0.6 %), call made on July 30, 2026, maturing on July 30, 2027 (29 d ago).
Firm-by-firm track record on Manhattan Associates
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Rosenblatt | 80 % | +37.5 % | 10 | $150 -33% |
| Raymond James | 58 % | +10.5 % | 12 | $240 +7% |
| Loop Capital | 50 % | +4.5 % | 6 | $215 -4% |
| Baird | 25 % | -8.1 % | 8 | $218 -3% |
| Truist Securities | 30 % | -10.9 % | 10 | $240 +7% |
| DA Davidson | 0 % | -22.1 % | 9 | $210 -6% |
| Benchmark | 83 % | +46.6 % | 6 | — |
| SunTrust Robinson Humphrey | 83 % | +42.5 % | 6 | — |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
- The most reliable firm on MANH, Raymond James (58% hit rate, 12 scored calls), targets $240 (call made on October 22, 2025, maturing on October 22, 2026) (+7%) in its most recent call.
⚠️ Reasons to hesitate
- Limited upside: the median target is only -5% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on MANH
Median target $213 (-5%) · 6 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Manhattan Associates now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $213 (-5%), and Raymond James (most reliable on MANH, 58%) targets $240. Weigh that against valuation and volatility. This is not personalized advice.
Is it too late to invest in Manhattan Associates?
The stated upside is small: the median target ($213) sits just -5% from the price ($224) (most reliable on MANH: Raymond James, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Manhattan Associates still worth investing in?
It depends on the gap between the price ($224) and its estimated value: analysts target $213 on median (-5%), with 100% buys (most reliable on MANH: Raymond James, 58%). Cross-check with their real reliability on MANH and the cautions above. Information, not advice.
What's the main risk in buying MANH?
Limited upside: the median target is only -5% from the current price.
→ Go deeper: the full Manhattan Associates profile (consensus, analyst reliability, price target, performance).